Evidence map›Paper›PMID 31833037›Full record

ArticleVirologica Sinica2020

A Deleted Deletion Site in a New Vector Strain and Exceptional Genomic Stability of Plaque-Purified Modified Vaccinia Ankara (MVA).

Ingo Jordan, Deborah Horn, Kristin Thiele, Lars Haag, Katharina Fiddeke, Volker Sandig

Open access · hybridAbstract read
In one paragraph

Article in Virologica Sinica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Ingo JordanProBioGen AG, Herbert-Bayer-Straße 8, 13086, Berlin, Germany. ingo.jordan@probiogen.de.ORCID http://orcid.org/0000-0003-2711-7252
Deborah HornProBioGen AG, Herbert-Bayer-Straße 8, 13086, Berlin, Germany.
Kristin ThieleProBioGen AG, Herbert-Bayer-Straße 8, 13086, Berlin, Germany.
Lars HaagVironova AB, Gävlegatan 22, 113 30, Stockholm, Sweden.
Katharina FiddekeProBioGen AG, Herbert-Bayer-Straße 8, 13086, Berlin, Germany.
Volker SandigProBioGen AG, Herbert-Bayer-Straße 8, 13086, Berlin, Germany.
Bayer (Germany) · DEKarolinska University Hospital · SERentschler Biopharma (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vectored vaccines based on highly attenuated modified vaccinia Ankara (MVA) are reported to be immunogenic, tolerant to pre-existing immunity, and able to accommodate and stably maintain very large transgenes. MVA is usually produced on primary chicken embryo fibroblasts, but production processes based on continuous cell lines emerge as increasingly robust and cost-effective alternatives. An isolate of a hitherto undescribed genotype was recovered by passage of a non-plaque-purified preparation of MVA in a continuous anatine suspension cell line (CR.pIX) in chemically defined medium. The novel isolate (MVA-CR19) replicated to higher infectious titers in the extracellular volume of suspension cultures and induced fewer syncytia in adherent cultures. We now extend previous studies with the investigation of the point mutations in structural genes of MVA-CR19 and describe an additional point mutation in a regulatory gene. We furthermore map and discuss an extensive rearrangement of the left telomer of MVA-CR19 that appears to have occurred by duplication of the right telomer. This event caused deletions and duplications of genes that may modulate immunologic properties of MVA-CR19 as a vaccine vector. Our characterizations also highlight the exceptional genetic stability of plaque-purified MVA: although the phenotype of MVA-CR19 appears to be advantageous for replication, we found that all genetic markers that differentiate wildtype and MVA-CR19 are stably maintained in passages of recombinant viruses based on either wildtype or MVA-CR.

Indexed as

Genetic VectorsGenomic InstabilitySequence DeletionVirus ReplicationAnimalsCell LineDucksGenotypePoint MutationRecombination, GeneticVaccinia virusViral Plaque AssayCR.pIXGenome stabilityModified vaccinia Ankara (MVA)MVA-CR19Suspension cell lineVaccine production

Identifiers

PMID31833037
PMCPMC7198643
OpenAlexW2995003801

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.